Surims Ltd Logo
 
 
 
 
 
 
Catalent Pharma Solutions Logo  
 
 
Basic Profile
 
If you'd like to claim this company profile for Catalent Pharma Solutions, please Contact Us.
 

Catalent Pharma Solutions News

The latest news, announcements and press releases from Catalent Pharma Solutions.

 
 
13
May
2021
13th May 2021
 

HBC Announces Global Innovation Partnership

Hofseth BioCare ASA (HBC), a Norwegian biotech company that develops high-value ingredients and finished products, today announced that it has begun a global innovation partnership with Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to develop a delayed-release formulation of HBC’s OmeGo® fish oil.

 
Read the full story »
 
 
10
May
2021
10th May 2021
 

Catalent buys another Belgian CDMO to boost fast-growing cell and gene therapy services

SOMERSET, N.J. and MONT-SAINT-GUIBERT, BELGIUM – May 6, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Promethera Biosciences, the leader in advanced therapy development for severe liver diseases, today announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 square-foot (3,010 square-meter) facility in Gosselies, Belgium. The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of Catalent’s pDNA service offering, which was recently acquired from Delphi Genetics to support the growing cell and gene therapy pipeline.

 
Read the full story »
 
 
08
April
2021
08th April 2021
 

Moderna, Catalent Enter Long-Term Strategic Vax Pact

CAMBRIDGE, Mass. and SOMERSET, N.J. – April 6, 2021 — Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the expansion of their strategic collaboration to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other investigational programs in Moderna’s pipeline, at Catalent’s biologics facility in Bloomington, Indiana.

 
Read the full story »
 
 
22
May
2020
22nd May 2020
 

Catalent to acquire Japanese facility to expand global clinical supply

Drug delivery technology provider Catalent will acquire a clinical packaging facility in Japan, in a deal made with Teva-Takeda Pharmaceuticals.
 
Read the full story »
 
 
10
January
2020
10th January 2020
 

Catalent Completes Purchase of BMS Site

Biologics fill-finish and oral solid dose facility located in Anagni, Italy.

 
Read the full story »
 
 
03
July
2019
03rd July 2019
 

Catalent Completes Acquisition Of Gene Therapy Leader Paragon

Catalent Completes Acquisition Of Gene Therapy Leader Paragon Bioservices, Inc. For $1.2 Billion

 
Read the full story »
 
 
03
July
2019
03rd July 2019
 

Catalent snaps up Novavax production sites and 100 employees in $18M deal

Another deal has been struck in the rapidly evolving market for gene therapy manufacturing. Just two months after Catalent jumped big time into the gene therapy realm, it is adding a couple of small vaccine production sites and a 100 employees to its operation.  

 
Read the full story »
 
 
06
July
2018
06th July 2018
 

Catalent Signs Agreement To Acquire Juniper Pharmaceuticals, Inc.

Catalent, Inc. the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division.
 
Read the full story »
 
 
20
July
2017
20th July 2017
 

Pfizer Partners With Catalent For The Manufacture Of Advil® Liqui-Gels® Minis

Somerset, N.J., – July 12, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that following a successful 20-year collaboration on the development and manufacture of Advil® Liqui-Gels® (ibuprofen), it has entered into an exclusive long-term supply agreement to produce the next generation of Pfizer Inc.’s leading over-the-counter (OTC) pain relief product with the launch of new Advil Liqui-Gels Minis, using Catalent’s innovative softgel platform OptiGel™ Mini technology.
 
Read the full story »
 
 
13
June
2017
13th June 2017
 

Catalent Completes Accucaps Acquisition To Expand Softgel Development And Manufacturing Capabilities And Capacity

SOMERSET, N.J. – February 16, 2017 — Catalent, Inc. (Catalent) (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the acquisition of Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed.
 
Read the full story »
 
 
31
January
2016
31st January 2016
 

Catalent continues to scout acquisitions and licensing in 2016

Catalent will pursue strategic acquisitions and licensing in 2016, said VP Marketing & Strategy Elliott Berger, noting growth areas include complex delivery technologies and specialised logistics.
 
Read the full story »
 
 
 

Claim This Profile

This is the News section of the company profile page for Catalent Pharma Solutions on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.

 
 
Catalent Pharma Solutions company details, activities, contacts and reviews.
 
Catalent Pharma Solutions partnership and licensing opportunities.
 
Catalent Pharma Solutions latest news, announcements and press releases.
 
Catalent Pharma Solutions documents, images and videos.
 
Catalent Pharma Solutions global factories, offices and locations.
 
Catalent Pharma Solutions legal and financial information.
 
 
 
 
 
 
 

About Us

Surims Ltd is a consultancy established in 2003 supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own on-boarding and supplier management activities. Further information on our software services can be found at https://www.surims.com.

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@pharmaservicesdirectory.com

 
 

© 2021 Surims Ltd | All Rights Reserved.